Artal Group’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History

Artal Group’s Portfolio FUSN Stock Details FUSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,005,500	Closed	-$9.7M	–	128
2023 Q4	$9.7M	Sell	1,005,500 -719,500	-42%	-$3.5M	0.32%	36
2023 Q3	$4.48M	Hold	1,725,000	–	–	0.19%	59
2023 Q2	$8.06M	Sell	1,725,000 -250,000	-13%	-$1.08M	0.25%	57
2023 Q1	$7.45M	Buy	1,975,000 +1,225,000	+163%	+$4.82M	0.44%	51
2022 Q4	$2.36M	Hold	750,000	–	–	0.13%	82
2022 Q3	$2.26M	Hold	750,000	–	–	0.1%	89
2022 Q2	$1.87M	Hold	750,000	–	–	0.1%	100
2022 Q1	$5.83M	Hold	750,000	–	–	0.24%	72
2021 Q4	$3.13M	Hold	750,000	–	–	0.08%	122
2021 Q3	$5.94M	Hold	750,000	–	–	0.13%	109
2021 Q2	$6.06M	Buy	750,000 +210,736	+39%	+$1.81M	0.12%	113
2021 Q1	$5.78M	Buy	+539,264	New	+$6.3M	0.1%	119

Other funds holding FUSN

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Deerfield Management New York $9.6B AUM 113.36% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $144B AUM 22.91% 1-Year Est. Return

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Artal Group's FUSN Position: Q1 2024 in Review

Artal Group sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q1 2024, closing a stake of 1,005,500 shares — an estimated $9.7M sold.

Artal Group first reported a position in FUSN in Q1 2021 and held it in 12 quarters. The position peaked at $9.7M in Q4 2023. 114 funds tracked by Wall St. Rank hold FUSN as of Q1 2024.

Artal Group reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q1 2024 after selling out during the quarter.
Artal Group sold 1,005,500 Fusion Pharmaceuticals Inc. Common Shares shares in Q1 2024, an estimated $9.7M.
Artal Group first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q1 2021 and held it in 12 quarters.
Artal Group's Fusion Pharmaceuticals Inc. Common Shares position peaked at $9.7M in Q4 2023.
114 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q1 2024.

Based on Artal Group's 13F filing for Q1 2024, filed 13 May 2024.